Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiaoji Decoction (XJD) is a traditional Chinese herbal prescription that has been utilized for decades in the treatment of cancer, particularly non-small cell lung cancer (NSCLC), to improve patient quality of life and survival. The therapeutic mechanism involves the activation of AMP-activated protein kinase alpha (AMPKα), which subsequently inhibits the transcription factor Sp1. This inhibition leads to the downregulation of DNA methyltransferase 1 (DNMT1), thereby suppressing tumor cell growth. Clinical research, such as studies conducted by the Guangdong Provincial Hospital of Traditional Chinese Medicine, has explored its use in combination with targeted therapies like erlotinib for patients with advanced NSCLC who are unsuitable for chemotherapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiaoji Decoction.